HomeAI · summaries
Storia in 8 fonti
Why Is Abivax Stock Sinking Tuesday? - Abivax (NASDAQ:ABVX)
Abivax shares plunge more than 35% as cancer cases reported in a Phase 3 trial overshadow strong efficacy results for ulcerative colitis drug.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
- ·
biopharmadive.com
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
